Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00222222
Status:
COMPLETED
Last Update Posted:
2012-02-16
First Post:
2005-09-13
Brief Title:
Mediators of Inflammation Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis
Sponsor:
Universitätsmedizin Mannheim
Organization:
Universitätsmedizin Mannheim
Study Overview
Official Title:
Mediators of Inflammation Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis
Status:
COMPLETED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Aims of the study were to find vascular markers of inflammation and endothelial damage during the course of severe sepsis in septic patients and the effects of treatment with anti-inflammatory medication such as Drotregocin alfa activated Another aim is to find new markers and gene polymorphisms for prognosis and mortality of patients with severe sepsis The hypothesis is that higher plasma concentrations of certain markers in septic patients are associated with a higher mortality rate
Detailed Description:
During the past years many investigators have focused on the immunological changes in sepsis disease and great attention has been paid to the development of practicable means of immunomonitoring Human activated protein C Drotrecogin alfa activated an important coagulation inhibitor plays a major role in regulating microvascular coagulation inflammation and immunology Little is known about prognostic vascular biomarkers during the time course of patients with severe sepsis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 02444 | None | None | None |